Astellas Pharma Inc.
Regarding the Recognition of Impairment Loss on Intangible Assets and Special Loss in Individual Financial Statements (Japanese GAAP)
Recorded an impairment loss on intangible assets of 16.4 billion yen and a special loss of 74.8 billion yen related to valuation loss on affiliate shares in FY2025 Q4. The impact on consolidated financial results is limited.
Key Figures
- Impairment Loss on Intangible Assets: 16.4 billion yen (FY2025 Q4)
- Valuation Loss on Affiliate Shares: 74.8 billion yen (Special Loss in Individual Financial Statements)
- Impact on Consolidated Profit and Loss: None (Eliminated)
AI要約
Regarding the Impairment Loss on Intangible Assets
Astellas Pharma, in relation to the gene therapy drug resamirigene bilparvovec (AT132) under development for patients with X-linked myotubular myopathy, has reviewed the value of AT132-related intangible assets due to the strategic discontinuation of the program and reallocation of resources to the next-generation gene therapy ASP2957. As a result, an impairment loss of 16.4 billion yen was recorded under other expenses in the FY2025 Q4 financial statements.
Recognition of Special Loss and Impact on Consolidated Financial Statements
Regarding shares of affiliate companies, the carrying amount of shares in the subsidiary Ogeda B.V. fell below its net realizable value, leading to a valuation loss on affiliate shares of 74.8 billion yen recognized as a special loss in the individual financial statements. This valuation loss is eliminated in the consolidated financial statements and therefore has no impact on consolidated earnings.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
